Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

SB 4 (Eticovo)

  Cat. No.:  DC23833   Featured
Chemical Structure
100874-08-6
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
BMP signaling agonist sb4 is a small molecule BMP signaling agonist with EC50 of 73.6 nM, enhances the efficacy of BMPs and activates endogenous BMP4 target genes.
Cas No.: 100874-08-6
Chemical Name: 2-(4-Bromobenzylsulfanyl)benzoxazole
Synonyms: BMP signaling agonist sb4;2-(4-Bromobenzylsulfanyl)benzoxazole;2-[(4-bromophenyl)methylsulfanyl]-1,3-benzoxazole;SB 4;HMS1585K19;2-((4-Bromobenzyl)thio)benzo[d]oxazole;2-[(4-bromophenyl)methylthio]benzoxazole;ST50478260;2-[[(4-Bromophenyl)methyl]thio]benzoxazole
SMILES: BrC1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])SC1=NC2=C([H])C([H])=C([H])C([H])=C2O1
Formula: C14H10BrNOs
M.Wt: 320.204301357269
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: BMP signaling agonist sb4 is a small molecule BMP signaling agonist with EC50 of 73.6 nM, enhances the efficacy of BMPs and activates endogenous BMP4 target genes; increases the phosphorylation of key second messengers (SMADs-1/5/9) and also increased expression of direct target genes (inhibitors of DNA binding, ID1 and ID3) in canonical BMP signaling.
Target: IC50: BMP4 signal[1]
In Vitro: BMP signaling agonist sb4 (0.05 μM-1 μM; 24 hours) induces phosphorylated SMAD-1/5/9 in a dose-dependent manner in PRECs cells under serum-starved conitions[1]. BMP signaling agonist sb4 (1 μM; 0-60 mins) enhances the efficacy of signaling at each concentration of rhBMP4 tested. This effect is most pronounced at low concentrations of rhBMP4, whereby sb4 increases BRE-luc expression 2-fold at 0.4 ng/ml of rhBMP4[1]. Western Blot Analysis[1] Cell Line: Primary mouse kidney epithelial cells (PRECs) Concentration: 0.05 μM-1 μM Incubation Time: 24 hours Result: Incresed p-SMAD-1/5/9 abundance in PRECs. Western Blot Analysis[1] Cell Line: BRE-Luc cells Concentration: 1 μM Incubation Time: 0min, 5 mins, 15 mins, 30 mins, 45 mins, 60 mins Result: Acted to stabilize p-SMAD-1/5/9 to enhance the transcriptional response.
References: [1]. Bradford STJ, et al. High-throughput screens for agonists of bone morphogenetic protein (BMP) signaling identify potent benzoxazole compounds.J Biol Chem. 2019 Mar 1;294(9):3125-3136.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC31074 Isopropyl myristate Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868 AZ14133346 AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865 TI17 ​​TI17​​ represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816 Nisoxetine Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641 GENZ-644282 TFA salt Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325 PSMA-617 TFA PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202 Fosaprepitant free acid Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748 O4I4 O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684 ZH8667 ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646 EB-PSMA-617 EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.
X